SCHEMBL10150191

SCHEMBL10150191

CN1CCc2c(nc(-c3ccccc3O)nc2N(C)C)C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.44
ALDH1A1 P00352 5/20 0.44
MAPT P10636 5/20 0.44
TDP1 Q9NUW8 3/20 0.44
KMT2A Q03164 2/20 0.44
LMNA P02545 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
GAA P10253 1/20 0.44
STAT6 P42226 1/20 0.44
PTK2B Q14289 1/20 0.44
HIF1A Q16665 1/20 0.44
MEN1 O00255 1/20 0.41
HPGD P15428 3/20 0.41
HSD17B10 Q99714 2/20 0.41
MAPK1 P28482 2/20 0.41
NPSR1 Q6W5P4 1/20 0.41
USP2 O75604 1/20 0.41
TSHR P16473 1/20 0.41
C5AR1 P21730 1/20 0.40
ADORA1 P30542 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8298136 0.85 C5AR1 (0.40) KDM4EALDH1A1MAPTTDP1KMT2A
SCHEMBL8298130 0.84 PDE10A (0.42) KDM4EALDH1A1MAPTTDP1KMT2A
SCHEMBL172777 0.84 ATR (0.41) KDM4EALDH1A1MAPTTDP1LMNA
SCHEMBL10149986 0.83 KMT2A (0.39) KDM4EALDH1A1MAPTTDP1KMT2A
SCHEMBL172736 0.82 BRS3 (0.48) KDM4EALDH1A1MAPTKMT2AGAA
SCHEMBL10150218 0.82 CFTR (0.42) HPGDADORA2A
SCHEMBL8299281 0.82 ALDH1A1 (0.49) KDM4EALDH1A1TDP1KMT2ALMNA
SCHEMBL8299286 0.82 ALDH1A1 (0.46) KDM4EALDH1A1TDP1KMT2ALMNA
SCHEMBL8298131 0.81 ATR (0.44) KDM4EALDH1A1MAPTTDP1KMT2A
SCHEMBL8297566 0.81 ALDH1A1 (0.48) KDM4EALDH1A1TDP1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120040935-A1 COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS VERTEX PHARMACEUTICALS, INC. (US) 2012-02-16 US disclosed
US-20120040935-A1 COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS VERTEX PHARMACEUTICALS, INC. (US) 2012-02-16 US disclosed
US-7968545-B2 Compositions useful as inhibitors of voltage-gated ion channels VERTEX PHARMACEUTICALS INC. (US) 2011-06-28 US disclosed
US-7968545-B2 Compositions useful as inhibitors of voltage-gated ion channels VERTEX PHARMACEUTICALS INC. (US) 2011-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120040935-A1 COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS KCNQ1, KCNN2, KCNH3 KDM4E 2477/4885ALDH1A1 3086/4885MAPT 1627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.